Food and Staples Retailing Drug Retail

  • Drugmakers want indemnity

    Drug companies may be looking for legal protection amid a massive demand for Ebola vaccines, reports CNBC's Meg Tirrell.

  • Walgreen's former CFO sued the drugstore operator, alleging executives defamed him in news reports that blamed him for errors in its forecast.

  • GW Pharma: Focused on epilepsy

    GW Pharma shares are down sharply after a study of its treatment for ulcerative colitis missed its primary endpoint in a mid-stage trial. GW Pharmaceuticals CEO Justin Gover, says the company's main focus is on its product for epilepsy.

  • Cannabis Expo: Pet food & more

    CNBC's Kate Rogers reports from the East Coast Cannabis Business Expo, on one pot entrepreneur taking CBD, which is an extract of the hemp plant, and putting it in pet food.

  • Weed, Inc.: The business of legal marijuana

    Medical marijuana, which is legal in 23 states and Washington, D.C., and recreational marijuana -- legal in Colorado and Washington State -- bring dispensaries and states healthy revenues, via taxes and fees. Watch a 90-second overview of the business of legal marijuana by the numbers.

  • Problems for potpreneurs

    CNBC's Kate Rogers reports on the uphill battle facing potpreneurs.

  • Tekmira soars on FDA news

    Tekmira said regulators in the U.S. and Canada authorized use of its experimental drug for Ebola through an expanded access program. CNBC's Meg Tirrell provides insight.

  • High at work

    A new survey from Mashable finds nearly 10 percent of Americans admit to smoking pot before heading into the office. CNBC's Kate Rogers shares the difficulties in testing employees.

  • Avanir up on Alzheimer's trial

    Avanir Pharma is up more than 60 percent, after the company said its drug was more effective in reducing agitation associated with Alzheimer's, compared with a placebo. CNBC's Meg Tirrell speaks to the company's CEO Keith Katkin.

  • Orexigen's obesity pill

    Orexigen's obesity pill is called Contrave, and it's been approved in the U.S. CNBC's Meg Tirrell reports.

  • The UN food price index has dipped to a four-year low as good weather has resulted in an oversupply of cereals and dairy imports have slowed.

  • Barry Rosenstein, founder and managing partner of Jana Partners

    Walgreen is naming Jana founder Rosenstein to its board and the activist investor will get a say in choosing at least one additional director.

  • Big change for pain drugs

    CNBC's Meg Tirrell reports the Drug Enforcement Administration is changing the rules around pain drugs like Vicodin. The drugs will be deemed "schedule 2 substances," versus the less restrictive "schedule 3."

  • Obesity treatment sales fall short

    CNBC's Meg Tirrell provides insight to the definition of obesity by the CDC, and which drug companies are working on treatments in the space.

  • Forest fire threatens illegal marijuana grows

    A massive fire in Northern California has so far burned close to 12,000 acres and injured 12 people. CNBC's Jane Wells reports on the costs to the state, as well as to marijuana growers.

  • Dr. Beth Bell, CDC Infectious Diseases Center, discusses the Ebola crisis in West Africa, and the risks to U.S. citizens. Bell explains current experimental treatments.

  • Pharma companies rush to help Ebola

    The CDC Director is testifying before Congress on Ebola, and pharma companies are scrambling to create drugs to help. CNBC's Meg Tirrell, and Michael Yee, RBC Capital Markets, discuss some of these companies.

  • Viagra's patent in China has expired and some analysts expect cheaper prices will bring a surge of demand for the storied erectile dysfunction drug.

  • The push back on Sovaldi

    Insurance companies are hurting from the high cost of hepatitis C drug Sovaldi. Arthur Caplan, NYU Langone Medical Center, and CNBC's Bertha Coombs, share their opinions.

  • The $84,000 drug debate

    CNBC's Bertha Coombs reports which insurance stocks are hurting from the high cost of hepatitis C Sovaldi.